Vol.58 No.1 January 2010
Clinical aspects of candidemia before and after the introduction of micafungin in Saitama Medical School Hospital
Department of Infectious Diseases and Infection Control, Saitama Medical School, 38 Morohongo, Moroyama-machi, Iruma-gun, Saitama, Japan
Abstract
The antifungal agent micafungin, developed in Japan, was approved for use in 2003 in treating. The proportion of Candida spp we compared prognosis and other clinical parameters among those treated for candidemia in pre-micafungin use in 2000/2003 and post-micafungin use in 2004/2007. Preuse cases numbered 84 and postuse cases 31. Candida albicans isolation was 52.4% in preuse and 40.0% in postuse. Candida parapsilosis accounted for 23.8% in preuse and 40.0% in postuse. The treatment of choice as an antifungal agent in 2000/2003 was fluconazole and micafungin thereafter. The mortality prognosis in those with candidemia was 46.0% in the preuse period, and 12.9% in postuse. This suggests that while micafungin has proven very useful in treating candidemia, it should still be determined whether the proportion of non-albicans Candida has increased.
Key word
candidemia, fluconazole, micafungin, Candida albicans, Candida parapsilosis
Received
December 26, 2008
Accepted
October 27, 2009
Jpn. J. Chemother. 58 (1): 14-17, 2010
